NCT06625320Phase 3Active not recruiting

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Study sponsor: Revolution Medicines, Inc. · RVMD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-06Estimated

Enrollment · participants500Actual

Source updated2026-06-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-27 · 1 field changed

Actual enrollment decreased by 1 participants

− Before

~~501 participants (actual)~~

+ After

500 participants (actual)

Check registry source

Posted 2025-12-12 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~460 participants (planned)~~

+ After

501 participants (actual)

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma

Treatments or interventions studied

RMC-6236Drug
GemcitabineDrug
nab-paclitaxelDrug
IrinotecanDrug
Liposomal irinotecanDrug
5-fluorouracilDrug
leucovorinDrug
OxaliplatinDrug

Primary outcomes · main study measures

Read the study measures

measure: Progression free survival (PFS) in the RAS G12-mutant population; description: PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by blinded independent central review (BICR); timeFrame: Up to approximately 3 years; measure: Overall survival (OS) in the RAS G12-mutant population; description: OS is defined as the time from randomization until death from any cause.; timeFrame: Up to approximately 3 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history